-
September 02, 2010
Bristol-Myers Squibb/Pfizer’s apixaban can more than halve the risk of stroke or systemic embolism compared with aspirin in patients with atrial fibrillation who cannot take warfarin, the results of the AVERROES trial have shown.
-
September 02, 2010
Companies “have only scratched the surface” in their efforts to understand patient psychology so that clinical trial protocols can be better geared to meeting recruitment targets, say consultants Cutting Edge Information.
-
September 02, 2010
The Institute of Clinical Research in India (ICRI) has formed a strategic partnership with Accenture to develop an educational programme in clinical research and pharmacovigilance.
-
August 31, 2010
Servier’s angina drug Procoralan (ivabradine) could significantly lower the risk of death and hospitalisation from chronic heart failure when added to standard CHF therapy, the results of the SHIFT trial indicate.
-
August 31, 2010
Doctors are increasingly encouraged to factor costs into their drug prescribing decisions but very few clinical trials actually detail these costs, a Canadian study has found.
-
August 31, 2010
IrisSys and Xcelience have signed a business alliance agreement to help pharmaceutical and biotechnology companies in North America streamline access to chemistry, manufacturing and controls (CMC) and regulatory expertise.
-
August 26, 2010
Nearly two thirds of clinical trials conducted under the US Paediatric Exclusivity provision involve at least one site outside the US, a new analysis suggests.
-
August 26, 2010
Early-stage contract research organisation Cetero Research has expanded its Clinical Dermatology and Transdermal Drug Delivery System (TDDS) services to four of its clinical facilities in the US and Canada.
-
August 26, 2010
Heavy use of special regulatory mechanisms, highly targeted agents and a focus on orphan indications have enabled leading biotechnology companies to produce a surprising number of innovative and profitable cancer therapies.
-
August 24, 2010
ClinTec has secured a £8 million investment from private equity firm Elephant Capital Plc, which has entered the clinical research space by taking a 28.6% stake in the UK-based contract research organisation.